UNSPSC 51151544: Pilocarpine hydrochloride

This classification denotes a cholinergic agonist with the molecular formula C11H16N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0WW6D218XJ, chemically known as 3-isopilocarpine, monohydrochloride but more generally known as pilocarpine hydrochloride, which bears US NIH Compound Identifier 4819. European Medicines Agency schedules Pilocarpine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14870MIG.

Most nations, for tariff and trade purposes, schedule pilocarpine hydrochloride under HS 29399990 and SITC 54149. As of Q4 2014, PILOCARPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pilocarpine hydrochloride bears US NLM identifiers UMLS ID C0770456 and NCI Concept Code C748. SMILES: CC[C@H]1[C@H](COC1=O)CC2CNCN2C.CL.

UNSPSC 51151544 Pilocarpine hydrochloride is a Commodity code that nominally designates a specific pharmaceutical ingredient, but recent state and local opportunities show a material mismatch between the code's pharmaceutical scope and the actual work being solicited. The two recent opportunities tagged to this code involve procurement of naloxone (an opioid antagonist) and direct-to-manufacturer prescription program administration—neither involving pilocarpine hydrochloride. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for community health initiatives, with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory market-intelligence inquiry designed to inform future formal procurement strategy around direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels.

Activity under this code spans county health departments and state health and human services agencies, though the recent-opportunity block shows limited volume. Geographic activity is visible in Florida and Texas, with no supporting evidence of activity in other jurisdictions. The Seminole County naloxone solicitation requires electronic bid submission through the county e-Procurement Portal, drug-free workplace certification, E-Verify compliance, and standard commercial insurance; FEMA funding is noted as a potential funding source, introducing federal compliance requirements including Clean Air Act and Federal Water Pollution Control Act adherence. The Texas RFI functions as a preliminary information-gathering mechanism without formal evaluation criteria, site visits, or binding timelines, designed to develop the state's future contracting approach before issuing a formal RFP. The code shows little recent activity directly aligned with pilocarpine hydrochloride procurement; business development professionals should verify whether this code is a reliable signal for future pharmaceutical opportunities or whether issuing bodies are applying the code inconsistently to unrelated drug-program solicitations.